Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.

摘要: BACKGROUND In a phase 1 study of pulse/continuous-dose erlotinib, no patient had disease progression in the central nervous system (CNS). This expansion cohort tested same regimen individuals with epidermal growth factor receptor (EGFR)–mutant lung cancers untreated brain metastases. METHODS Patients not received EGFR tyrosine kinase inhibitors or radiation for metastases. All 1200 mg erlotinib on days and 2 50 3 to 7 weekly. The primary endpoints were overall CNS response rates (according version 1.1 Response Evaluation Criteria Solid Tumors). RESULTS Between May 2015 August 2016, 19 patients enrolled. Forty-two percent target lesions, median size lesions was 13 mm. Overall, 14 (74%; 95% confidence interval [CI], 51%-89%) partial responses. rate metastases 75%. progression-free survival 10 months (95% CI, reached). Only (16%) progression. To date, 4 required at some time during their course. adverse events (any grade) seen 10% more rash, diarrhea, nausea, an increase alanine aminotransferase, fatigue. CONCLUSIONS Pulse/continuous-dose produced 74% 75% EGFR-mutant control persisted even after elsewhere. Although this did improve delay emergence T790M, it prevented could be useful situations which is critical. Cancer 2017. © 2017 American Society.